This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Discussing the recent data from the phase 2 IGNAZ clinical trial of Felzartamab in patients with IgAN
Ticker(s): BIIBWho's the expert?
Institution: USC
- Associate Professor of Medicine at Keck-USC School of Medicine & Medical Director of the CKD program and the Renal, Hypertension and Transplant Clinic at the LAC+USC.
- Currently treats over 200 patients with Anemia-CKD.
- Research focuses on advancing kidney dialysis, liver dialysis and providing a support system for the MOF/MODS multisystem failures; has conducted major pharmaceutical sponsored phase II-IV clinical trials in hypertension, anemia, iron, and secondary hyperparathyroidism.
Interview GoalTo discuss the current treatment landscape and the potential of Felzartamab, a therapy being developed by Biogen for the treatment of IgAN.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
